Total and H‐specific growth/differentiation factor 15 levels are unaffected by liraglutide or naltrexone/bupropion administration

Abstract

AbstractAimTo investigate growth/differentiation factor 15 (GDF‐15) levels in response to antiobesity medications, namely, liraglutide (Lira) and naltrexone/bupropion (N/B), in individuals with overweight or obesity.Materials and MethodsThis was a prospective, non‐randomized clinical trial with a two‐arm, parallel design. A total of 42 individuals with overweight or obesity without type 1 or type 2 diabetes mellitus were enrolled. The participants received either Lira 3 mg or N/B 32/360 mg, along with diet and exercise, according to comorbidities, cost and method of administration. Participants underwent clinical and laboratory measurements at baseline, as well as at the 3‐ and 6‐month time points. Anthropometric measurements and body composition analysis via bioelectrical impendence analysis were performed. Total blood samples for GDF‐15 and H‐specific GDF‐15 were collected in the fasting state and every 30 min for 3 h after the consumption of a standardized mixed meal.ResultsOverall, participants' weight was reduced by 9.29 ± 5.34 kg at Month 3 and 11.52 ± 7.52 kg at Month 6. Total and H‐specific GDF‐15 levels did not show significant changes during the mixed meal compared to values before the meal when all participants were examined at baseline, and at 3 and 6 month follow‐ups. No statistical significance was found when participants were examined by subgroup (Lira vs. N/B). No significant differences between treatment groups in postprandial area under the curve (AUC) or incremental AUC values were found at baseline or in the follow‐up months with regard to total and H‐specific GDF‐15 levels.ConclusionNeither total nor H‐specific GDF‐15 levels are affected by Lira or N/B treatment in patients with overweight or obesity.